<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160767</url>
  </required_header>
  <id_info>
    <org_study_id>2015/ST/135-3</org_study_id>
    <nct_id>NCT04160767</nct_id>
  </id_info>
  <brief_title>Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients</brief_title>
  <acronym>VIVOMIXX</acronym>
  <official_title>Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) on Vitamin B6, B12, 25'OH D, Folic Acid and Omocystein Levels, Metabolic and Inflammatory Status, and Gut Microbiota Metabolomics in a Cohoort of Celiac Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Celiac disease is a disorder caused by a disregulation of the immune system which leads to
      immune response to gluten. Diet therapy is the gold standard of treatment, and the only
      effective one. Macronutrients and micronutrients deficiency (vitamin D, folic acid, vitamin
      B12, vitamin B6, iron and zinc), which is in any case far more common in patients who don't
      follow gluten free diet, can persist in a subset of patients who follow gluten-free diet.
      Supplementation of vitamins in these patients may have a beneficial role. A recent study in a
      murine model showed that supplementation with probiotic VIVOMIXX® leads to an increase in
      expression of vitamin D receptors in proximal and distal colon.

      This is an interventional controlled randomized double blind study, which evaluates the
      effect of VIVOMIXX® on vitamin status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      90 patients with celiac disease who follow gluten free diet will be enrolled. INCLUSION
      CRITERIA

        -  Celiac disease (diagnosis made according to ESPGHAN criteria) EXCLUSION CRITERIA

        -  Supplementation with pre/probiotics in the previous 3 months;

        -  Antibiotic therapy in the previous 3 months;

        -  Comorbidity with other acute (in the previous 3 months) or chronic gastrointestinal
           disorders

        -  Supplementation with group B vitamins for any reason

      Patients enrolled will be referred to Paediatric Gastroenterology Service in San Paolo
      Hospital at the time of enrollement (T0) and after intervention therapy (T1, + 4 months).

      Patients will be randomized in one of the two arms of intervention (VIVOMIXX once a day for 4
      months versus placebo once a day for 4 months).

      VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus
      thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis
      DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM
      24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of
      bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES
      S.A. - Lugano Switzerland.

      At each time point clinic evaluation, nutritional assessment and blood testing will be made.
      Data collection will include:

        -  Systemic arterial blood pressure;

        -  Anthropometric measures (height, weight, body mass index, waist circumference, triceps
           skinfold)

        -  Clinical evaluation including presence/absence of oral aphtous stomatitis

        -  Measure of chinolinic acid, serotonin, ghrelin (analysis will be made at Istituto
           Malattie Infettive, Università La Sapienza, Roma).

        -  Dosing of inflammatory markers (analysis will be made at Health Sciences Department, San
           Paolo Hospital).

        -  Metabolomics on stool samples (analysis will be made at Bologna University, Dipartimento
           di Scienze e Tecnologie Agro-Alimentari, Cesena, with a financial fund by MENDES S.A. -
           Lugano Switzerland).

        -  Routine blood testing including complete blood cell count, vitamin B6, acid folic,
           vitamin B12, vitamin D 25'OH, fasting glucose, fasting insulin, total cholesterol, LDL
           and HDL cholesterol, Apolipoprotein A1 and Apolipoprotein B, triglycerides, homocistein,
           auto-antibody anti endomisium and anti-transglutaminase,

        -  Genetic testing for MTHFR gene

        -  ESR, highly sensitive CRP, IL6, TNFalfa, fibrinogen

        -  Fecal calprotectin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in vitamin B6, folic acid, vitamin B12 and 25'OH vitamin D levels in blood</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in homocysteine levels in blood</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in ghrelin, chinolinic acid and serotonin levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fecal metabolomics (including production of short chain fatty acids verified by gas-chromatography)</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in highly sensitive C reactive protein levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in erythrocite sedimentation rate</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fibrinogen blood levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in IL-6 blood levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Tumor Necrosis Factor alfa blood levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body mass index</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systemic arterial systolic and diastolic blood pressure</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in height</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in waist circumference</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Entity of reduction of triceps skinfold thickness</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prevalence of aphtous stomatitis</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in chinolinic acid, serotonin, ghrelin levels in blood</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in complete cell blood count</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL cholesterol levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LDL cholesterol levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Apolipoprotein A1 levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Apolipoprotein B levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose levels</measure>
    <time_frame>T0 T1 (+4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting insulin levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in auto-antibody anti endomisium titer</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in auto-antibody anti-transglutaminase titer</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal calprotectin levels</measure>
    <time_frame>Time point 0: day 0 Time point 1: after 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of wildtype allele of MTHFR gene by gene sequencing</measure>
    <time_frame>Time point 0: day 0 (at the enrollement)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Vivomixx</intervention_name>
    <description>VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Gluten free diet</intervention_name>
    <description>Gluten free diet will be encouraged in both arms</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Celiac disease (diagnosis made according to European Society for Paediatric
             Gastroenterology Hepatology and Nutrition)

        Exclusion Criteria:

          -  Supplementation with pre/probiotics in the previous 3 months;

          -  Antibiotic therapy in the previous 3 months;

          -  Comorbidity with other acute (in the previous 3 months) or chronic gastrointestinal
             disorders

          -  Supplementation with group B vitamins for any reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale San Paolo</name>
      <address>
        <city>Milan</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Verduci, MD PhD Assistant Professor</last_name>
      <phone>+39 0281844508</phone>
      <email>elvira.verduci@unimi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 9, 2019</last_update_submitted>
  <last_update_submitted_qc>November 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Elvira Verduci</investigator_full_name>
    <investigator_title>Principal Investigator, Paediatrician, University of Milan Researcher</investigator_title>
  </responsible_party>
  <keyword>Celiac disease</keyword>
  <keyword>Gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

